# DNANO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dnano

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.dnanotech.bio
- Latest round: Angel (May 1, 2022)
- Investors on record: 3

## About

Established in 2022 and based in Hangzhou, China, DNANO is a biotech company that focuses on developing nucleic acid nanocarrier technology. The company's founder, Dr. Baoquan Ding, graduated from New York University with a degree in chemistry and more than 10 years of experience in nucleic acid nanocarrier technology and was a scientist at the National Center for Nanoscience. In May 2023, it raised pre-series A funding led by new investor Together To Miracle, with participation from returning investors Ji Liu Zero Capital, Mureng Investment, and other unspecified investors.  In September 2025, DNANO closed a venture funding from returning investor Jiliuling Capital.

The company's self-developed nucleic acid nanocarrier structure design and sequence optimization platform can be used to deliver different types of drugs including small molecules, small nucleic acids, and long-chain nucleic acids. Its products are used in the field of oncology, metabolic diseases, and rare diseases.

The company will use the pre-series A funding for the advancement of a pipeline of organ-specific targeted small nucleic acid drugs.

## Funding rounds

- Angel, May 1, 2022 — Mureng Investment, TigerYeah Capital, Jiliuling Capital

## Investors

- Mureng Investment — Angel
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Angel
- Jiliuling Capital (https://capitalatlas.ai/funds/jiliuling-capital) — Angel